IN THE COURT OF ARBITRATION FOR SPORT

FLOYD LANDIS	)	
	)	
Appellant,	)	
	)	
V.	)	**CAS 2007/A/1394**
	)	
UNITED STATES ANTI-DOPING AGENCY	)	
	)	
Respondent.	)	
	)	

USADA'S WITNESS DESIGNATIONS

The United States Anti-Doping Agency ("USADA"), identifies the following witnesses that USADA may call to testify in this matter by means of written statement. Set forth below is a general summary of each witness's anticipated testimony. USADA reserves the right to supplement these statements as requested by the Panel or as otherwise necessary. USADA may not provide statements from all of the witnesses identified, particularly where USADA determines that testimony may be duplicative or where USADA is able to reach a stipulation with Appellant regarding non-contested matters.

USADA notes as well that a number of USADA's witnesses are in France and many will speak to very discrete issues, if they provide testimony at all, which makes their physical presence at the hearing in New York City unnecessarily burdensome and expensive.

USADA will attempt to provide key witnesses for in-person examination; however, because of the timing of the hearing, certain witnesses below will be made available for cross-examination, if necessary, solely by teleconference.

1. **Dr. Cedric Shackleton, Children's Hospital Oakland Research Institute.** Dr. Shackleton is one of the world's leading experts in the field of steroid metabolism. He has also published in the area of the use of IRMS to detect exogenous testosterone use.

Dr. Shackleton may provide a witness statement containing a brief summary of his experience and background as well as statements based on his experience, research and review of documents in this case.

Dr. Shackleton's testimony will be directed to the following general areas: the metabolism of testosterone generally and testosterone metabolism in the context of Mr. Landis' IRMS results; and, the use of IRMS analysis to detect doping with exogenous testosterone.

Specific points that may be addressed by Dr. Shackleton include but are not limited to his opinions and the basis for those opinions that a significant difference between one single

metabolite minus endogenous reference compound pair provides a sufficient scientific basis for a positive IRMS test.

Dr. Shackleton may review any conclusions offered or testimony given by Appellant's witnesses in the AAA Hearing and may address any issues or defenses raised by Appellant and/or his experts as needed, including, if necessary, through rebuttal testimony. Dr. Shackleton would likely be available in person during the hearing for cross examination.

2. **J. Thomas Brenna, Ph.D., Professor of Nutritional Science, Cornell University.** Dr. Brenna is one of the world's leading experts on IRMS analysis. Dr. Brenna has expertise in the use of IRMS analysis to detect the existence of exogenous testosterone and has significant expertise related to software related to IRMS analysis. He will provide a witness statement regarding the accuracy and reliability of the data provided by LNDD regarding Appellant's samples. His witness statement may also discuss the operation of IRMS instrument, software and the relevant quality controls related to the analysis. This discussion may include discussion of the importance of and proper means to utilize retention time and relative retention time in IRMS analysis. He may also provide testimony regarding the reprocessing of the samples that occurred at the request of Appellant.

Dr. Brenna may review any conclusions offered or testimony given by Appellant's experts at the AAA Hearing and may address any issues or defenses raised by Appellant and/or his experts as needed. Dr. Brenna may also, if necessary, respond to Appellant's experts through rebuttal testimony. Dr. Brenna will be available in person during the hearing for cross examination regarding the subjects in his witness statement.

3. **Richard V. Clark, Senior Director, Metabolic Therapeutic Area, Metabolic CEED, GlaxoSmithKline Research and Development, Research Triangle Park, NC.** Dr. Clark may submit a witness statement in response to claims made by Appellant's witnesses at the AAA Hearing and in Appellant's Brief regarding the known metabolism of testosterone and Appellant's test results and any other claim or defense asserted by Appellant or his witnesses that is within Dr. Clark's area of expertise. Dr. Clark's witness statement may also reference, explain or refute the testimony of any witness who may testify regarding the physiological effects of testosterone. Dr. Clark likely will be available in person during the hearing for cross examination.

4. **Dwight Matthews, Professor and Chairman, Department of Chemistry, College of Arts and Science, University of Vermont.** Dr. Matthews is an expert in the area of using stable isotope tracers to study human amino acid and protein metabolism. He participated in the development of the IRMS instrument and method, and is therefore expert in both instrument functionality and analysis of IRMS results. Dr. Matthews may provide a witness statement discussing the reliability of the IRMS analysis in this case. Dr. Matthews may discuss any claim or defense asserted by Appellant or his witnesses that is within Dr. Matthew's area of expertise. Dr. Matthews likely will be available for cross examination in person regarding the matters in his witness statement during the hearing.

5. **Dr. Christiane Ayotte, Director Montreal WADA Accredited Laboratory** Dr. Ayotte will provide a witness statement regarding her experience and background and the

experience and research of the Montreal laboratory. Dr. Ayotte may also discuss her participation as a member of the WADA Laboratory Committee and various sub-committees and her participation as a scientific review advisor for the International Amateur Athletic Federation. Dr. Ayotte's may also address her research and experience in the area of identification of exogenous testosterone through GC/MC (T/E Ratio) and IRMS, and her review of exhibits in this case.

Specific points that may be addressed by Dr. Ayotte include, but are not limited to, her opinions and the basis for those opinions regarding the relevant WADA Technical Documents and that Appellant's sample would have been declared positive by her laboratory; the reliability of the IRMS analysis in this case; LNDD's WADA and ISO accreditation; LNDD's quality controls, methods and chromatography; the results of analysis of Appellant's other Tour samples; LNDD's compliance with chain of custody requirements; anti-doping laboratory procedures, and any other matters within the scope of her expertise.

It is anticipated that Dr. Ayotte may review any conclusions offered or testimony give by Appellant's experts and address any issues or defenses raised by Appellant and/or his experts as needed, including, if necessary, through rebuttal testimony. Dr. Ayotte will likely be available in person during the hearing for cross examination regarding the subjects in her witness statement.

6. **Wilhelm Schänzer, Ph.D., Director, Institute of Biochemistry of the German Sports University Cologne.** Dr. Schänzer testified and was subject to cross examination at the AAA Hearing. Due to scheduling conflicts, he is unavailable to testify at the CAS Hearing. USADA may submit, along with other witness statements in this case, portions of Dr. Shanzer's prior testimony and cross examination that shall serve as his testimony in this matter.

7. **Janine Jumeau, Analytical Precision, Ltd.** Janine Jumeau was a Product Engineer for VG Isogas and Product Manager for VG Isotech. In this role, she was responsible for the development of the Isochrom IRMS (the predecessor of the Isoprime) and the design of the interface between a gas chromatograph and an isotope ratio mass spectrometer. She had an active role in research and development at VG, including the evaluation of the Isochrom OS/2-based software system. As such, she can provide information about the reliability of the Isochrom v 1.67-2 software as applied to the Isoprime IRMS used by LNDD. Ms. Jumeau may provide a witness statement regarding the reliability of the Isoprime IRMS on the days of the A and B analysis based on the results of controls and standards run on those days. She may also discuss instrument linearity with regard to the results in question. Ms. Jumeau may also provide information regarding the operation of IRMS instrument. Ms. Jumeau will likely be available during the hearing for cross examination regarding the subjects in her witness statement.

8. **Cynthia Mongongu, LNDD Analytical Chemist.** Ms. Mongongu testified extensively at the AAA Hearing. She will submit a witness statement for this hearing regarding similar topics covered during the AAA hearing including her role concerning Appellant's Stage 17 samples and/or Appellant's other B Samples, including specifically the activities reflected on the documents in the Document Packages for such samples on which her name or initials appear and the events in which she is identified as having been involved or allegedly involved in documents from the AAA Hearing or Appellant's Brief filed for this hearing. Ms. Mongongu

likely will be available in person during the hearing for cross examination regarding the subjects in her witness statement

9. **Claire Frelat, LNDD Analytical Chemist.** Ms. Frelat testified extensively at the AAA Hearing. Ms. Frelat will provide a witness statement for this hearing regarding topics similar to those covered during the AAA hearing including her role concerning Appellant's Stage 17 B sample and/or Appellant's other B Samples, including specifically the activities reflected on the documents in the Document Packages for such samples on which her name or initials appear and the events in which she is identified as having been involved or allegedly involved in documents from the AAA Hearing or Appellant's Brief filed for this hearing. Ms. Frelat likely will be available in person during the hearing for cross examination regarding the subjects in her witness statement.

10. **Dr. Corinne Buisson, IRMS Supervisor LNDD**. Dr. Buisson may provide a witness statement regarding her role concerning Appellant's Stage 17 samples and Appellant's other B Samples, including specifically the activities reflected on the documents in the Document Packages for such samples on which her name or initials appear and the events in which she is identified as having been involved or allegedly involved in documents from the AAA Hearing or Appellant's Brief filed for this hearing.

She may also testify concerning accreditation of LNDD by WADA, inspections and audits of LNDD by ISO, LNDD's standard operating procedures, the competence of Ms. Mongongu and Ms. Frelat in performing GCMS and IRMS analyses, compliance with the International Standard for Laboratories, including technical documents, other LNDD quality control, and quality assurance measures, standard operating procedures and LNDD security measures. If Dr. Buisson provides a witness statement, she likely will be available in person at the hearing for cross examination.

11. **Other LNDD Witnesses.** Esther Cerpolini, M. Garcia, Franck Neveu, Laurent Martin and Marjorie Cariou may provide witness statements regarding their roles handling Appellant's sample bottles These witnesses will be available for cross examination via teleconference or video conference. Agnes Gaillard may provide a witness statement regarding her recopying on document LNDD0440.

12. **Gerard Le Petit, President, Quad Service.** Mr. Le Petit is the president of a company that provides routine maintenance and repair services for IRMS machines through a contract with the machine maker, Agilent. He will submit a witness statement regarding his service call to LNDD in April 2006, the steps he takes in his service calls generally and on that one in particular, including changing out a column to perform tests and the reason for the appearance in certain LNDD documentation that two different columns were used in the IRMS machine when that could not have been the case. Mr. Le Petit likely will be available in person during the hearing for cross examination regarding the subjects in his witness statement.

13. **Sean Petty, Chief Operating Officer, USA Cycling**. Mr. Petty may provide a witness statement as a representative of USA Cycling confirming that the Leadville Trail 100 mountain bike race is a USA Cycling sanctioned event. Mr. Petty will not be available in person at the hearing but if necessary will be made available for cross examination via teleconference.

14. **Patrik Sinkewitz, professional cyclist**. Mr. Sinkewitz is a German cyclist who previously rode for team T-Mobile. He is an accomplished elite cyclist who has participated in the Tour de France and won the Tour of Germany in 2004. Mr. Sinkewitz may provide a witness statement explaining his use of testosterone and the fact that for a time his use of testosterone was not detected and other aspects of testosterone doping. Mr. Sinkewitz will likely be available by video conference for cross examination at the hearing.

15. **Floyd Landis**. Mr. Landis is the Appellant in this matter and will be examined regarding all facts and circumstances related to his Adverse Analytical Finding during Stage 17 of the 2006 Tour de France, including, but not limited to, all statements he has made related to this case.

16. **Other USADA Witnesses**. USADA also designates for potential direct, cross, or rebuttal examination all witnesses designated, endorsed, or called by Appellant.

USADA's objections as to witnesses are set forth in its Response Brief, transmitted herewith. USADA reserves the right with permission of the Panel to call additional witnesses and/or expert witnesses as needed based on receiving any future submissions from Appellant and also as necessary as unforeseen witnesses are identified by USADA or otherwise come forward with relevant information. USADA further reserves the right to call any witness necessary for impeachment or rebuttal.

Dated this 31st day of January, 2008.

United States Anti-Doping Agency



Richard R. Young
Daniel J. Dunn
Jennifer A. Sloan
Holme Roberts & Owen LLP
90 S. Cascade Ave., Suite 1300
Colorado Springs, CO 80903

Matthew S. Barnett
Barnett & Barnett P.C.
830 Tenderfoot Hill Rd, Suite 350
Colorado Springs, CO 80906